ArticleJournal of virology2001
Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications.
Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Characterization of the function of Adenovirus L4 gene products and their impact on AAV vector production.Molecular therapy. Methods & clinical development · 2024Article
- AAV production in stable packaging cells requires expression of adenovirus 22/33K protein to allow episomal amplification of integrated rep/cap genes.Scientific reports · 2023Article
- Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses.Clinical and vaccine immunology : CVI · 2017Article
- Amino acid exchanges in the putative nuclear export signal of adenovirus type 5 L4-100K severely reduce viral progeny due to effects on hexon biogenesis.Journal of virology · 2013Article
- Endoplasmic reticulum aminopeptidase-1 functions regulate key aspects of the innate immune response.PloS one · 2013Article
- Faithful chaperones.Cellular and molecular life sciences : CMLS · 2011Review
- Use of DAF-displaying adenovirus vectors reduces induction of transgene- and vector-specific adaptive immune responses in mice.Human gene therapy · 2011Article
- Generation of cell lines to complement adenovirus vectors using recombination-mediated cassette exchange.BMC biotechnology · 2010Article
- Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.International journal of cancer · 2010Article
- beta-Arrestins modulate Adenovirus-vector-induced innate immune responses: differential regulation by beta-arrestin-1 and beta-arrestin-2.Virus research · 2010Article
- Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor.Journal of innate immunity · 2010Article
- CR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies.Gene therapy · 2009Article
- Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.Cancer gene therapy · 2009Article
- Arginine methylation of human adenovirus type 5 L4 100-kilodalton protein is required for efficient virus production.Journal of virology · 2009Article
- Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses.Journal of innate immunity · 2009Article
- Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors.Gene therapy · 2008Article
- Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent.Gene therapy · 2008Article
- Article
- Viral subversion of apoptotic enzymes: escape from death row.Annual review of microbiology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The 100K protein has a number of critical roles vital for successful completion of the late phases of the adenovirus (Ad) life cycle. We hypothesized that the introduction of deletions within the 100K gene would allow for the production of a series of new classes of Ad vector, including one that is replication competent but blocked in the ability to carry out many late-phase Ad functions. Such a vector would have potential for several gene therapy applications, based upon its ability to increase the copy number of the transgene encoded by the vector (via genome replication) while decreasing the side effects associated with Ad late gene expression. To efficiently produce 100K-deleted Ad ([100K-]Ad) vectors, an E1- and 100K-complementing cell line (K-16) was successfully isolated. Transfection of an [E1-,100K-]Ad vector genome into the K-16 cells readily yielded high titers of the vector. After infection of noncomplementing cells, we demonstrated that [100K-]Ad vectors have a significantly decreased ability to express several Ad late genes. Additionally, if the E1 gene was present in the infected noncomplementing cells, [100K-]Ad vectors were capable of replicating their genomes to high copy number, but were significantly blocked in their ability to efficiently encapsidate the replicated genomes. Injection of an [E1-,100K-]Ad vector in vivo also correlated with significantly decreased hepatotoxicity, as well as prolonged vector persistence. In summary, the unique properties of [100K-]Ad vectors suggest that they may have utility in a variety of gene therapy applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.